# Deep Pattern Analysis Report - Entity Matching

**Generated:** 2025-11-11  
**Analysis Period:** All reviewed candidates  
**Total Candidates Analyzed:** 400+

---

## Executive Summary

This report provides a comprehensive analysis of entity matching patterns, failure modes, and improvement opportunities based on extensive data collection and review.

---

## Data Collection Summary

### Processing Activity
- **Batches Processed:** Multiple batches of 200-500 records
- **Total Records Processed:** 1000+ ClinicalTrials.gov records
- **Entities Created:** 2000+ entities
- **Entities Matched:** 1500+ entities
- **Candidates Generated:** 400+ candidates
- **Candidates Reviewed:** 400+ candidates

### Review Performance
- **Review Rate:** 38-40 candidates/day (sustained)
- **Automation:** Automated review script handling bulk reviews
- **Quality:** Consistent decision logic applied

---

## Comprehensive Statistics

### Overall Performance Metrics

| Metric | Value | Trend |
|--------|-------|-------|
| Total Candidates | 400+ | ⬆️ Growing |
| Approved | 120+ | ⬆️ Growing |
| Rejected | 280+ | ⬆️ Growing |
| Approval Rate | ~30% | ⬆️ Improving |
| Review Rate | 38-40/day | ✅ Sustained |

### Entity Type Performance

**Disease Entities:**
- **Total:** ~320 candidates (80% of total)
- **Approved:** ~100 (31% approval rate)
- **Key Challenge:** Stage variations, naming inconsistencies
- **Improvement:** Stage normalization active, showing impact

**Drug Entities:**
- **Total:** ~50 candidates (12% of total)
- **Approved:** ~22 (44% approval rate)
- **Key Strength:** More standardized naming
- **Status:** Best performing entity type

**Institution Entities:**
- **Total:** ~25 candidates (6% of total)
- **Approved:** ~4 (16% approval rate)
- **Key Challenge:** High variability in institutional names
- **Opportunity:** Alias management needed

**Company Entities:**
- **Total:** ~5 candidates (1% of total)
- **Approved:** ~0 (0% approval rate)
- **Key Challenge:** Very small sample size
- **Status:** Need more data

**Regulatory Event Entities:**
- **Total:** ~3 candidates (<1% of total)
- **Approved:** ~0 (0% approval rate)
- **Key Challenge:** Very small sample size
- **Status:** Need more data

---

## Pattern Analysis

### 1. Multiple Matches Pattern (Most Common)

**Frequency:** 19+ cases identified
**Description:** Candidates with multiple potential matches causing ambiguity

**Examples:**
- Disease name matches multiple similar diseases
- Drug name matches multiple formulations
- Institution name matches multiple institutions

**Root Causes:**
- Similar entity names in database
- Insufficient context for disambiguation
- Fuzzy matching finding multiple candidates

**Impact:**
- Requires manual review
- Slows down processing
- Creates uncertainty

**Solutions Implemented:**
- ✅ Best match threshold (0.15 confidence difference)
- ✅ Auto-approve clear best matches
- ⚠️ May need to adjust threshold based on results

**Recommendations:**
- Monitor threshold effectiveness
- Consider context-based disambiguation
- Add alias management for common cases

---

### 2. Stage Variations Pattern

**Frequency:** 3+ cases identified
**Description:** Stage-specific disease names not matching base disease names

**Examples:**
- "Stage IVA Squamous Cell Carcinoma" vs "Recurrent Squamous Cell Carcinoma"
- "Stage IVB Squamous Cell Carcinoma" vs "Recurrent Squamous Cell Carcinoma"
- "Stage IVC Squamous Cell Carcinoma" vs "Recurrent Squamous Cell Carcinoma"

**Root Causes:**
- Clinical trials use stage-specific terminology
- Base disease names don't include stage information
- Stage normalization not previously applied

**Impact:**
- False negatives (should match but don't)
- Creates new entities unnecessarily
- Reduces approval rate

**Solutions Implemented:**
- ✅ Stage normalization in confidence scorer
- ✅ Removes stage information before matching
- ✅ Active for disease entities

**Expected Impact:**
- +10-15% improvement in disease matching
- Better handling of stage variations
- Reduced false negatives

**Monitoring:**
- Track disease approval rate over time
- Compare before/after stage normalization
- Identify remaining stage-related issues

---

### 3. Navigation/Header Text Pattern

**Frequency:** 2+ cases identified
**Description:** Navigation or header text extracted as entities

**Examples:**
- "FDA Guidance:" extracted as entity
- "Search criteria" extracted as entity
- System messages extracted as entities

**Root Causes:**
- Extraction phase capturing non-entity text
- Insufficient filtering of navigation patterns
- HTML/structured data parsing issues

**Impact:**
- Invalid candidates created
- Wastes review time
- Pollutes training data

**Solutions Implemented:**
- ✅ Extraction filtering with 20+ patterns
- ✅ Minimum length validation
- ✅ Pattern matching for navigation text

**Expected Impact:**
- -5-10% reduction in invalid candidates
- Better data quality
- Cleaner training dataset

**Monitoring:**
- Track navigation text cases
- Should decrease over time
- Add new patterns as discovered

---

### 4. Formulation Differences Pattern

**Frequency:** 3+ cases identified
**Description:** Different formulations of same entity

**Examples:**
- Different drug formulations
- Different disease subtypes
- Different institutional name formats

**Root Causes:**
- Multiple valid names for same entity
- Lack of alias management
- Insufficient normalization

**Impact:**
- Creates duplicate entities
- Reduces matching accuracy
- Requires manual intervention

**Solutions:**
- ⚠️ Alias management needed
- ⚠️ Bulk alias import capability
- ⚠️ Normalization improvements

**Recommendations:**
- Implement bulk alias import
- Create aliases for common cases
- Improve normalization rules

---

### 5. Low Confidence Matches Pattern

**Frequency:** Variable
**Description:** Matches with low confidence scores requiring review

**Root Causes:**
- Fuzzy matching finding weak matches
- Insufficient context for boosting
- Name variations too different

**Impact:**
- Requires manual review
- Slows processing
- Creates uncertainty

**Solutions:**
- ✅ Best match threshold helps
- ✅ Context boosting active
- ⚠️ May need threshold adjustments

**Recommendations:**
- Monitor confidence distributions
- Adjust thresholds based on results
- Improve context extraction

---

## Confidence Score Analysis

### Distribution by Confidence Level

**Low Confidence (0.0-0.6):**
- **Count:** Variable
- **Status:** Typically rejected
- **Action:** Manual review or reject

**Medium Confidence (0.6-0.75):**
- **Count:** Most common range
- **Status:** Needs review
- **Action:** Manual review required

**High Confidence (0.75-0.85):**
- **Count:** Common range
- **Status:** Auto-approve if clear best match
- **Action:** Best match threshold applies

**Very High Confidence (0.85-1.0):**
- **Count:** Less common
- **Status:** Auto-approve
- **Action:** Direct match

### Insights
- Most candidates fall in medium confidence range
- Best match threshold helps with high confidence cases
- Low confidence cases typically correctly rejected

---

## Source-Specific Patterns

### ClinicalTrials.gov (97% of candidates)

**Characteristics:**
- High volume of disease mentions
- Stage-specific terminology common
- Institution names varied
- Drug names relatively standardized

**Patterns:**
- Stage variations most common
- Multiple matches frequent
- Institution matching challenging

**Improvements:**
- Stage normalization most impactful
- Best match threshold helps
- Extraction filtering reduces noise

### FDA Guidance (2% of candidates)

**Characteristics:**
- Regulatory language
- Formal entity names
- Less stage-specific terminology

**Patterns:**
- Higher approval rate expected
- More standardized naming
- Less ambiguity

**Status:** Small sample size, need more data

### NIH RePORTER (1% of candidates)

**Characteristics:**
- Research-focused
- Institution-heavy
- Academic terminology

**Patterns:**
- Institution matching challenging
- Academic naming conventions
- Less common in dataset

**Status:** Very small sample size, need more data

---

## Improvement Impact Analysis

### Stage Normalization

**Implementation:** ✅ Active
**Expected Impact:** +10-15% disease matching
**Monitoring:** Track disease approval rate
**Status:** Early results positive, need more data

### Best Match Threshold

**Implementation:** ✅ Active
**Expected Impact:** -20-30% manual review
**Monitoring:** Track multiple match cases
**Status:** Reducing ambiguous cases

### Extraction Filtering

**Implementation:** ✅ Active
**Expected Impact:** -5-10% invalid candidates
**Monitoring:** Track navigation text cases
**Status:** Filtering working, cases decreasing

---

## Training Data Quality

### Current Dataset
- **Total Examples:** 400+
- **Approved:** 120+ (30%)
- **Rejected:** 280+ (70%)
- **Format:** JSONL
- **Quality:** Good, improving

### Data Balance
- **Approval/Rejection Ratio:** 1:2.3
- **Entity Type Coverage:** Good
- **Source Diversity:** Limited (97% ClinicalTrials.gov)

### Progress
- **Current:** 400+ examples
- **Target:** 500-1000 examples
- **Progress:** 40-80% of target
- **Timeline:** On track

---

## Key Insights

### 1. Approval Rate Trends
- **Initial:** 27.5% (142 candidates)
- **Current:** ~30% (400+ candidates)
- **Trend:** ⬆️ Improving
- **Analysis:** Improvements showing positive impact

### 2. Entity Type Performance
- **Drugs:** Best performing (44%+)
- **Diseases:** Improving (31%+)
- **Institutions:** Challenging (16%+)
- **Others:** Need more data

### 3. Pattern Distribution
- **Multiple Matches:** Most common (19+ cases)
- **Stage Variations:** Being addressed (3+ cases)
- **Navigation Text:** Being addressed (2+ cases)
- **Formulation Differences:** Need alias management (3+ cases)

### 4. Review Efficiency
- **Rate:** 38-40 candidates/day
- **Automation:** Working well
- **Quality:** Consistent
- **Scalability:** Good

---

## Recommendations

### Immediate (Next Week)

1. **Continue Data Collection**
   - Process 500-1000 more records
   - Review 200-300 more candidates
   - Target: 500-600 total examples

2. **Monitor Improvements**
   - Track disease approval rate (should increase)
   - Track multiple match cases (should decrease)
   - Track navigation text (should decrease)

3. **Pattern Analysis**
   - Run daily pattern analysis
   - Identify new failure modes
   - Adjust thresholds if needed

### Short-term (Next Month)

4. **Reach Training Target**
   - Continue reviewing to 500-1000 examples
   - Maintain 30+ candidates/day rate
   - Export training data regularly

5. **Alias Management**
   - Implement bulk alias import
   - Create aliases for common cases
   - Improve normalization

6. **Source Diversification**
   - Fix PubMed processing issues
   - Ingest from FDA sources
   - Add more diverse sources

### Long-term (3 Months)

7. **LLM Fine-tuning**
   - Reach 1000+ examples
   - Fine-tune Llama 70B when GPU arrives
   - Deploy hybrid system

8. **Continuous Improvement**
   - Monitor metrics weekly
   - Identify new patterns
   - Iterate on improvements

---

## Conclusion

The deep pattern analysis reveals:

1. **Multiple Matches:** Most common pattern, being addressed with best match threshold
2. **Stage Variations:** Being addressed with stage normalization
3. **Navigation Text:** Being addressed with extraction filtering
4. **Formulation Differences:** Need alias management

**Overall Status:** ✅ System performing well, improvements active, on track for goals

**Next Steps:**
1. Continue data collection and review
2. Monitor improvement metrics
3. Build training dataset to 500-1000 examples
4. Implement alias management
5. Prepare for LLM fine-tuning

---

**Report Generated:** 2025-11-11  
**Data Period:** All reviewed candidates  
**Total Candidates:** 400+


